Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Patient-reported outcomes from DREAMM-8 study (Bela/Pom/dex vs. Vel/Pom/dex) show a greater proportion of pts in the BelaMaf group had meaningful improvement (≥10 points) at most visits, but more blurred vision (43%) and fatigue.”
Title: Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
Authors: Meletios A Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Ivan Spicka, Jakub Radocha, Paweł Robak, Kihyun Kim, Michele Cavo, Kazuhito Suzuki, Jodie Wilkes, Simon McNamara, Amy Phillips-Jones, Kristin Morris, Farrah Pompilus, Molly Purser, Neal Sule, Brandon Kremer, Angely Loubert, Laurine Bunod, Manal M’Hari, Xiaoou L Zhou, Giulia Fulci, María-Victoria Mateos, and Suzanne Trudel
You can read the Full Article in The Lancet Haematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
